Рекомендации ESPEN-ESPGHAN-ECFS по диетотерапии при муковисцидозе у младенцев, детей и взрослых

324

Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. J Cyst Fibres 2008;7:137-41

325

Carr SB, Dinwiddie R. Annual review or continuous assessment? J R Soc Med 1996;89 (Suppl. 27):3-7

326

Rust P, Eichler I, Renner S, Elmadfa I. Long-term oral beta-carotene supple-mentation in patients with cystic fibrosis – effects on antioxidative status and pulmonary function. Ann Nutr Metab 2000;44:30-7

327

Shenkin A. Physiological function and deficiency states of vitamins. In: Sobotka L, editor. Basics in clinical nutrition. 4th ed. Prague: Galen; 2011. p. 145–53

328

Brei C, Simon A, Krawinkel MB, Naehrlich L. Individualized vitamin A supplementation for patients with cystic fibrosis. Clin Nutr 2013;32:805-10

329

Brei C, Simon A, Krawinkel MB, Naehrlich L. Individualized vitamin A supplementation for patients with cystic fibrosis. Clin Nutr 2013;32:805-10

330

Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. Am J Clin Nutr 2006;84:174-82

331

Graham-Maar RC, Schall JI, Stettler N, Zemel BS, Stallings VA. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. Am J Clin Nutr 2006;84:174-82

332

Myhre AM, Carlsen MH, Bohn SK, Wold HL, Laake P, Blomhoff R. Water- miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 2003;78:1152-9

333

IOM (Institute of Medicine). Dietary reference intakes: vitamin A, K, iron, zinc, and other elements. Washington, DC: National Academies Press; 2001. p. 773

334

Smets KJ, Barlow T, Vanhaesebrouck P. Maternal vitamin A deficiency and neonatal microphthalmia: complications of biliopancreatic diversion? Eur J Pediatr 2006;165:502-4

335

Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, et al. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr 2008;153:554-9

336

Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999;135:601-10

337

Hall WB, Sparks AA, Aris RM. Vitamin d deficiency in cystic fibrosis. Int J Endocrinol 2010;2010:218691

338

Robberecht E, Vandewalle S, Wehlou C, Kaufman JM, De Schepper J. Sunlight is an important determinant of vitamin D serum concentrations in cystic fibrosis. Eur J Clin Nutr 2011;65:574-9

339

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012;97:1082-93

340

Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, et al. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr 2008;153:554-9

341

Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibres 2011;10(Suppl. 2):S16-23

342

EFSA panel on dietetic products nutrition and allergies. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA J 2012;10. 2813, 45pp

343

Braegger C, Campoy C, Colomb V, Decsi T, Domellof M, Fewtrell M, et al. Vitamin D in the healthy European paediatric population. J Pediatr Gastroenterol Nutr 2013;56:692-70

344

IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, D.C.: The National Academies Press; 2011

345

Robberecht E, Vandewalle S, Wehlou C, Kaufman JM, De Schepper J. Sunlight is an important determinant of vitamin D serum concentrations in cystic fibrosis. Eur J Clin Nutr 2011;65:574-9

346

IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, D.C.: The National Academies Press; 2011

347

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012;97:1082-93

348

EFSA panel on dietetic products nutrition and allergies. Scientific opinion on the tolerable upper intake level of vitamin D. EFSA J 2012;10. 2813, 45pp

349

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012;97:1082-93

350

Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxy vitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 2012;95:1357-64

351

Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012;97:1082-93

352

Shepherd D, Belessis Y, Katz T, MortonJ, Field PJaffe A. Single high-dose oral vitamin D(3) (stoss) therapy – a solution to vitamin D deficiency in children with cystic fibrosis? J Cyst Fibres 2013;12:177-82

353

Shepherd D, Belessis Y, Katz T, MortonJ, Field PJaffe A. Single high-dose oral vitamin D(3) (stoss) therapy – a solution to vitamin D deficiency in children with cystic fibrosis? J Cyst Fibres 2013;12:177-82

354

Mailhot G Vitamin D bioavailability in cystic fibrosis: a cause for concern? Nutr Rev 2012;70:280-93

355

Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999;135:601-10

356

Lancellotti L, D'Orazio C, Mastella G, Mazzi G. Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr 1996;155:281-5

357

Lagrange-Puget M, Durieu I, Ecochard R, Abbas-Chorfa F, Drai J, Steghens JP, et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr Pulmonol 2004;38: 43-9

358

Cantin AM, Bilodeau G, Ouellet C, Liao J, Hanrahan JW. Oxidant stress suppresses CFTR expression. Am J Physiol Cell Physiol 2006;290:C262-70

359

Shenkin A. Physiological function and deficiency states of vitamins. In: Sobotka L, editor. Basics in clinical nutrition. 4th ed. Prague: Galen; 2011. p. 145–53

360

Huang SH, Schall JI, Zemel BS, Stallings VA. Vitamin E status in children with cystic fibrosis and pancreatic insufficiency. J Pediatr 2006;148:556-9

361

Winklhofer-Roob BM, van't HofMA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr 1996;63: 722-8

362

Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr 1999;135:601-10

363

Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibres 2010;9: 24-8

364

Huang SH, Schall JI, Zemel BS, Stallings VA. Vitamin E status in children with cystic fibrosis and pancreatic insufficiency. J Pediatr 2006;148:556-9

365

Nast D, Paniagua C, Anderson P. Cystic fibrosis: a clinician's tool for management of care advancing into the adult population. J Am Acad Nurse Pract 2012;24:625-32

366

Dougherty KA, Schall JI, Stallings VA. Suboptimal vitamin К status despite supplementation in children and young adults with cystic fibrosis. Am J Clin Nutr 2010;92:660-7

367

Rashid M, Durie P, Andrew M, Kalnins D, Shin J, Corey M, et al. Prevalence of vitamin К deficiency in cystic fibrosis. Am J Clin Nutr 1999;70:378-82

368

Gallagher M. Intake: the nutrients and their metabolism. In: Mahan L, Escort- Stump S, Raymond J, editors. Krause's food and the nutrition care process. St Louis, MO: Elsevier Saunders; 2012. p. 32–128

369

Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibres 2011;10(Suppl. 2):S16-23

370

Conway SP, Wolfe SP, Brownlee KG, White H, 01-droyd B, Truscott JG, et al. Vitamin К status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005;115:1325-31

371

Rashid M, Durie P, Andrew M, Kalnins D, Shin J, Corey M, et al. Prevalence of vitamin К deficiency in cystic fibrosis. Am J Clin Nutr 1999;70:378-82

372

Sermet-Gaudelus I, Bianchi ML, Garabedian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibres 2011;10(Suppl. 2):S16-23

373

Drury D, Grey VL, Ferland G, Gundberg C, Lands LC. Efficacy of high dose phylloquinone in correcting vitamin К deficiency in cystic fibrosis. J Cyst Fibres 2008;7:457-9

374

Dougherty KA, Schall JI, Stallings VA. Suboptimal vitamin К status despite supplementation in children and young adults with cystic fibrosis. Am J Clin Nutr 2010;92:660-7

375

Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin К supplementation for cystic fibrosis. Cochrane Database Syst Rev 2011:CD008482

376

Drury D, Grey VL, Ferland G, Gundberg C, Lands LC. Efficacy of high dose phylloquinone in correcting vitamin К deficiency in cystic fibrosis. J Cyst Fibres 2008;7:457-9

377

Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin К supplementation for cystic fibrosis. Cochrane Database Syst Rev 2011:CD008482

378

Gallagher M. Intake: the nutrients and their metabolism. In: Mahan L, Escort- Stump S, Raymond J, editors. Krause's food and the nutrition care process. St Louis, MO: Elsevier Saunders; 2012. p. 32–128

379

Borowitz D, Konstan MW, O'Rourke A, Cohen M, Hendeles L, Murray FT. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther 2007;12:47-52

380

Haupt ME, Kwasny MJ, Schechter MS, McColley SA. Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis. J Pediatr 2014;164. 1110-1115

381

Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep 2007;9:116-22

382

Brady MS, Garson JL, Krug SK, Kaul A, Rickard KA, Caffrey HH, et al. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc 2006;106:1181-6

383

Trapnell ВС, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibres 2009;8:370-7

384

Colombo C, Fredella C, Russo MC, Faelli N, Motta V, Valmarana L, et al. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas 2009;38:693-9

385

Kashirskaya NY, Kapranov N1, Sander-Struckmeier S, Kovalev V Safety and efficacy of Creon(R) Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibres 2014;14:275-81

386

Munck A, Duhamel JF, Lamireau T, Le Luyer B, Le Tallec C, Bellon G, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibres 2009;8:14-8

387

Graff GR, Maguiness K, McNamara J, Morton R, Boyd D, Beckmann K, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010;32:89-103

388

Graff GR, McNamara J, Royall J, Caras S, Forssmann K. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. Clin Drug Investig 2010;30:351-64